Aspect Partners
SUPN icon

Aspect Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Aspect Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.24K Hold
52
– – ﹤0.01% 512
2026
Q2 		$2.42K Hold
52
– – ﹤0.01% 500
2026
Q1 		$2.69K Hold
52
– – ﹤0.01% 445
2025
Q4 		$2.58K Hold
52
– – ﹤0.01% 481
2025
Q3 		$2.48K Buy
+52
New +$2.09K ﹤0.01% 508

Other funds holding SUPN

Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Campbell Newman Asset Management
Campbell Newman Asset Management Milwaukee, Wisconsin $1.33B AUM 26.63% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $451M AUM 22.13% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
James Investment Research
James Investment Research Alpha, Ohio $936M AUM 24.49% 1-Year Est. Return

Aspect Partners's SUPN Position: Q3 2026 in Review

Aspect Partners held its Supernus Pharmaceuticals (SUPN) position steady in Q3 2026 at 52 shares worth $2.24K. The position accounts for ﹤0.01% of the portfolio, ranked #512.

Aspect Partners first reported a position in SUPN in Q3 2025 and has held it in 5 quarters since. The position peaked at $2.69K in Q1 2026. 51 funds tracked by Wall St. Rank hold SUPN as of Q3 2026.

  • Aspect Partners held 52 shares of Supernus Pharmaceuticals worth $2.24K as of Q3 2026.
  • Aspect Partners left its Supernus Pharmaceuticals share count unchanged in Q3 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #512 holding.
  • Aspect Partners first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Aspect Partners's Supernus Pharmaceuticals position peaked at $2.69K in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.